Evidence map›Paper›PMID 34527551›Full record

ArticleGland surgery2021

Development and validation of nomograms for predicting survival and recurrence in patients with parotid gland cancer.

Zhigong Wei, Zhuang Zhang, Lianlian Yang, Ling He, Zheran Liu, Yan He, Jingjing Wang, Xiaoli Mu, Ruidan Li, Yan Huang and 1 more

Abstract read
In one paragraph

Article in Gland surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhigong WeiDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Zhuang ZhangState Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Department of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu, China.
Lianlian YangDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Ling HeDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Zheran LiuDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Yan HeDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Jingjing WangDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Xiaoli MuDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Ruidan LiDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Yan HuangDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Xingchen PengDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo develop nomograms for predicting recurrence risk and long-term survival in patients with parotid gland cancer (PGC).

methodsA total of 301 consecutive patients with PGC who underwent surgery were enrolled and randomly divided into a training cohort (n=210) and a validation cohort (n=91). Predictive nomograms were constructed based on the independent indicators of overall survival (OS) and disease-free survival (DFS) as determined by multivariate Cox regression analysis. The discrimination and calibration of nomograms were evaluated using C-indices and calibration curves.

resultsSix independent predictors of OS were identified. Incorporating these factors, the nomogram showed good concordance statistics of 0.84 and 0.78 in predicting the 5-year OS in the training and validation cohorts. Five independent predictors of DFS were identified and integrated into the nomogram. The concordance statistics were 0.84 and 0.74 in predicting the 5-year DFS in the training and validation cohorts. The predictive performance of the nomograms outperformed the TNM model. Additionally, the patients were divided into two groups according to the nomogram score, and significant differences in OS and DFS were observed between the high risk and low risk groups. Finally, the role of postoperative treatments was evaluated based on the risk stratification; patients at high risk of disease recurrence showed an improvement in DFS after receiving postoperative treatments.

conclusionsThe nomogram showed good performance in predicting both OS and DFS in patients with PGC. It might be useful for selecting patients for postoperative treatments.

Indexed as

nomogramParotid gland cancer (PGC)prognosissurvival

Identifiers

PMID34527551
PMCPMC8411081

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.